Condition: Epithelial Ovarian Cancer · Ovarian Carcinoma · Sponsor: Radboud University Medical Center
This goal of this single arm, single center, exploratory phase I/II clinical trial is to learn more about the immunological efficacy, safety and feasibility of an autologous tumor lysate-loaded autologous XP-DC (cDC1)-based vaccine in patients with ovarian cancer.
This description comes directly from the study's public registry record.
Bouke Koeneman, MD · +31 (0)24 361 76 00 · bouke.koeneman@radboudumc.nl
Always discuss trial participation with your own doctor first.
| Radboud University Medical Center | Nijmegen, Gelderland, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05773859